Blog
RSS FeedFeatured
-
Post-2010 Psychedelics: An Expert-Panel Review
A ~65,000-word, thirteen-chapter interdisciplinary review of post-2010 psychedelic developments — clinical evidence, receptor biology and neuroplasticity, regulatory landscape, methodology critique, and sociocultural context including Indigenous reciprocity. Verified-citation, placebo-honest, post-Lykos.
Recent Posts
-
Ch. II — Chemistry and pharmacology
Structural scaffolds, synthesis, stability, and pharmacokinetics for psilocybin/psilocin, DMT, LSD, 5-MeO-DMT, and the fluoroethyl lysergamides.
-
Ch. VI — Clinical evidence: addiction, PTSD, anorexia, OCD
Psilocybin in AUD and tobacco cessation; the MAPP1/MAPP2 MDMA-AT case study; small-sample signals; ibogaine sidebar.
-
Ch. VIII — Fluoroethyl lysergamides
Structural pharmacology and harm-reduction epistemology of FLUORETH-LAD, FP-LAD, and the 1Fe-LSD ferrocenyl naming collision.
-
Ch. VII — Mebufotenin (5-MeO-DMT) clinical program
Two competing Phase 2b programmes — Beckley/atai BPL-003 and GH Research GH001 — and the implausibly-large GH001 effect-size decomposition.